Charles River Laboratories’ Post

If you missed Crystal Reitman’s presentation, Understanding the Challenges and Guidelines of Cell and Gene Therapy within Viral Clearance, at BPI US West, the on-demand version is now live! Don’t miss Crystal's discussion on the impact of ICH Q5A R2 and important viral safety principles. Watch now: https://okt.to/bkhNoT

The March/April issue of Retina Specialist is out now! Inside, multiple experts cover topics such as gene therapy for nAMD, the impact of anti-VEGF biosimilars, pearls for port delivery system refills, a rundown on Eylea HD & more. Read the new issue at www.Retina-Specialist.com #retina #retinaspecialist

As the year 2023 comes to an end, here is a recap of our on-demand webinars. Now you can catch up on what you missed on topics from cell and gene therapy to biopharma 4.0 and much more. Watch Now: https://lnkd.in/gU2FhGMr

ICYMI: Listen to Dr. Salvador Rico, CMO of Encoded Therapeutics Inc., discuss the company's gene therapy and overall program looking to tackle #DravetSyndrome https://lnkd.in/eZkjigEh #InternationalEpilepsyDay Dravet Syndrome Foundation

Have you read our recently released target product profile (TPP) guide and want to learn more about how to develop an effective TPP for successful therapy adoption? Join our webinar on the 31st of January titled 'Developing a robust target product profile (TPP) for successful therapy adoption', where Cell and Gene Therapy Catapult’s experts in #MarketAccess, #RegulatoryAffairs and #NonClinical strategy will talk through the guide, discuss the value of a TPP and how to approach building one. Register now: https://buff.ly/3RqT2nC #TargetProductProfile #CellTherapies #GeneTherapies #TherapyDevelopers

Listen to Dr. Salvador Rico, CMO of Encoded Therapeutics Inc., discuss the company's gene therapy and overall program looking to tackle #DravetSyndrome #InternationalEpilepsyDay Dravet Syndrome Foundation

Are you looking to improve your understanding of the characteristics of a target product profile (TPP) and learn how to create a robust TPP to increase the likelihood of successful adoption of your #AdvancedTherapy? The Cell and Gene Therapy Catapult are hosting a webinar titled 'Developing a robust target product profile (TPP) for successful therapy adoption' on the 31st January where some of our key experts will be discussing our recently released TPP guide, the importance of a TPP and how to approach building one. Learn more: https://buff.ly/3RqT2nC #TargetProductProfile #CellTherapies #GeneTherapies #NonClinical

Ever wondered about the intricate web of logistics behind #cellandgenetherapy #clinicaltrials? From sourcing specialized equipment to navigating regulatory requirements, every step is crucial in bringing innovative treatments to patients in need. We understand the nuances of these complex supply chains and have developed an end-to-end process to support your cell and gene therapy trial every step of the way. » https://bit.ly/3V8YOOd

This paper presents an improved anion exchange analytical method . It delivers enhanced separation of full AAV capsids from other common product-related impurities such as aggregates, and empty, partially filled, high density, or damaged capsids. The improved anion exchange analytical method has been shown to be applicable for different AAV serotypes.